Systematic review: Antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 10, 2003, Pages 1215-1227

  Moayyedi, P ^a   Soo, S ^b   Deeks, J ^c   Forman, D ^d   Harris, A ^e   Innes, M ^f   Delaney, B ^f  

^a CITY HOSPITAL   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e KENT AND SUSSEX HOSPITAL   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; BISMUTH CITRATE; BISMUTH SALICYLATE; BISMUTH SALT; CIMETIDINE; CISAPRIDE; DOMPERIDONE; HISTAMINE H2 RECEPTOR ANTAGONIST; METOCLOPRAMIDE; OMEPRAZOLE; PLACEBO; PROKINETIC AGENT; RANITIDINE; SUCRALFATE;

CLINICAL TRIAL; DRUG EFFICACY; DYSPEPSIA; HUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTACIDS; BISMUTH; CISAPRIDE; DRUG THERAPY, COMBINATION; DYSPEPSIA; GASTROINTESTINAL AGENTS; GASTROINTESTINAL TRANSIT; HISTAMINE H2 ANTAGONISTS; HUMANS; SUCRALFATE; TREATMENT OUTCOME;

EID: 0037606062     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01575.x     Document Type: Review

References (64)

1. Moayyedi P, Axon AT. Is there a rationale for eradication of Helicobacter pylori? Cost-benefit: the case for. Br Med Bull 1998; 54: 243-50.
2. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
3. Williams B, Luckas M, Ellingham JH, Dain A, Wicks AC. Do young patients with dyspepsia need investigation? Lancet 1988; 2: 1349-51.
4. Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12: 1055-65.
5. Champion MC, MacCannell KL, Thomson AB, et al. A double-blind randomized study of cisapride in the treatment of non-ulcer dyspepsia. The Canadian Cisapride Nud Study Group. Can J Gastroenterol 1997; 11: 127-34.
6. Chung JM. Cisapride in chronic dyspepsia: results of a double-blind, placebo-controlled trial. Scand J Gastroenterol (Suppl) 1993; 195: 11-4.
7. Dobrilla G, Comberlato M, Steele A, Vallaperta P. Drug treatment of functional dyspepsia. A meta-analysis of randomized controlled clinical trials. J Clin Gastroenterol 1989; 11: 169-77.
8. Allescher M, Hartung J, Bockenhauff A, Knapp G, Wienbeck Q. Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies. Scand J Gastroenterol 2001; 36: 934-41.
9. Talley NJ. Non-ulcer dyspepsia: myths and realities. Aliment Pharmacol Ther 1991; 5(Suppl): 62.
10. Bytzer P, Moller Hansen J, Schaffalittzky de Muckadell O. Treatment of non-ulcer dyspepsia: are prokinetics effective? Scand J Gastroenterol 2002; 37: 617-20.
11. Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990; 335: 205-8.
12. Soo S, Moayyedi P, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database of Systematic Reviews [computer file] 2000; CD001960.
13. Working Party. Management of dyspepsia: report from a Working Party. Lancet 1988; i: 576-8.
14. Talley NJ, Colin-Jones DG, Koch KL, Koch M, Nyren O, Stanghellini V. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991; 4: 145-60.
15. Casiraghi A, Ferrara A, Lesinigo E. Cimetidine vs antacids in non-ulcer dyspepsia. Curr Ther Res Clin Exp 1986; 39: 397(Abstract).
16. Misra SP, Dwivedi M, Misra V, Agarwal SK. Sucralfate versus ranitidine in non-ulcer dyspepsia: results of a prospective, randomized, open, controlled trial. Indian J Gastroenterol 1992; 11: 7-8.
17. Al-Quorain A, Larbi EB, Al-Shedoki F. A double-blind, randomized, placebo-controlled trial of cisapride in Saudi Arabs with functional dyspepsia. Scand J Gastroenterol 1995; 30: 531-4.
18. Bekhti A, Rutgeerts L. Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying. Postgrad Med J 1979; 55(Suppl.): 2.
19. De Nutte N, Van Ganse W, Witterhulghe M, Defrance P. Relief of epigastric pain in nonulcer dyspepsia: controlled trial of the promotility drug cisapride. Clin Ther 1989; 11: 62-8.
20. Francois I, De Nutte N. Nonulcer dyspepsia: effect of the gastrointestinal prokinetic drug cisapride. Curr Ther Res 1987; 41: 891-8.
21. Hannon R. Efficacy of cisapride in patients with nonulcer dyspepsia. A placebo-controlled study. Curr Ther Res Clin Exp 1987; 42: 814-22.
22. Hansen JM, Bytzer P, Schaffalitzky de Muckadell O. Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia. Am J Gastroenterol 1998; 93: 368-74.
23. Kellow JE, Cowan H, Shuter B, et al. Efficacy of cisapride therapy in functional dyspepsia. Aliment Pharmacol Ther 1995; 9: 153-60.
24. Rosch W. Cisapride in non-ulcer dyspepsia. Results of a placebo-controlled trial. Scand J Gastroenterol 1987; 22: 161-4.
25. De Groot GH, De Both PSM. Cisapride in functional dyspepsia in general practice. A placebo-controlled, randomized, double-blind study. Aliment Pharmacol Ther 1997; 11: 193-9.
26. Agorastos I, Akriviadis E, Goulis G. Effect of cisapride in nonulcer dyspepsia: a placebo-controlled trial. Curr Ther Res Clin Exp 1991; 49: 870-7.
27. Jian R, Ducrot F, Ruskone A, et al. Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. A double-blind placebo-controlled evaluation of cisapride. Dig Dis Sci 1989; 34: 657-64.
28. Delattre M, Malesky M, Prinzie A. Symptomatic treatment of non-ulcer dyspepsia with cimetidine. Curr Ther Res 1985; 37: 980-91.
29. Gotthard R, Bodemar G, Brodin U, Jonsson KA. Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol 1988; 23: 7-18.
30. Hadi S. Clinical investigation of ranitidine in patients with gastritis. Clin Ther 1989; 11: 590-4.
31. Kelbaek H, Linde J, Eriksen J, Mungaard S, Moesgaard F, Bonnevie O. Controlled clinical trial of treatment with cimetidine for non-ulcer dyspepsia. Acta Med Scand 1985; 217: 281-7.
32. Nesland AA, Berstad A. Effect of cimetidine in patients with non-ulcer dyspepsia and erosive prepyloric changes. Scand J Gastroenterol 1985; 20: 629-35.
33. Saunders JH, Oliver RJ, Higson DL. Dyspepsia: incidence of a non-ulcer disease in a controlled trial of ranitidine in general practice. Br Med J Clin Res Ed 1994; 1986: 665-8.
34. Singal AK, Kumar A, Broor SL. Cimetidine in the treatment of non-ulcer dyspepsia: results of a randomized double-blind, placebo-controlled study. Curr Med Res Opin 1989; 11: 390-7.
35. Muller P, Hotz J, Franz E, Simon B. Ranitidin in der Behandlung der Non-Ulcer-Dyspepsie. Eine placebo-kontrollierte Studie in der Bundesrepublic Deutschland. Arzneim-Forsch/Drug Res 1994; 10: 1130-2.
36. Blum AL, Arnold R, Stolte M, Fischer M, Koelz HR. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. Gut 2000; 47: 473-80.
37. Olubuyide IO, Atoba MA. Non-ulcer dyspepsia in Nigerians: clinical and therapeutic results. Scand J Gastroenterol Suppl 1986; 124: 83-7.
38. Kang JY, Tay HH, Wee A, Guan R, Math MV, Yap I. Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double blind placebo controlled study. Gut 1990; 31: 476-80.
39. Kazi JI, Jafarey NA, Alam SM, et al. A placebo controlled trial of bismuth salicylate in Helicobacter pylori associated gastritis. J Pakistan Med Assoc 1990; 40: 154-6.
40. Lambert JR, Dunn K, Borromeo M, Korman MG, Hansky J. Campylobacter pylori - a role in non-ulcer dyspepsia? Scand J Gastroenterol Suppl 1989; 160: 7-13.
41. Loffeld RJ, Potters HV, Stobberingh E, Flendrig JA, van Spreeuwel JP, Arends JW. Campylobacter associated gastritis in patients with non-ulcer dyspepsia: a double blind placebo controlled trial with colloidal bismuth subcitrate. Gut 1989; 30: 1206-12.
42. Vaira D, Holton J, Ainley C, et al. Double blind trial of colloidal bismuth subcitrate versus placebo in Helicobacter pylori positive patients with non-ulcer dyspepsia. Ital J Gastroenterol 1992; 24: 400-4.
43. Goh KL, Parasakthi N, Peh SC, Wong NW, Lo YL, Puthucheary SD. Helicobacter pylori infection and non-ulcer dyspepsia: the effect of treatment with colloidal bismuth subcitrate. Scand J Gastroenterol 1991; 26: 1123-31.
44. Kumar M, Yachha SK, Aggarwal R, et al. Healing of chronic antral gastritis: effect of sucralfate and colloidal bismuth subcitrate. Indian J Gastroenterol 1996; 15: 90-3.
45. Gudjonsson H, Oddsson E, Bjornsson S, et al. Efficacy of sucralfate in treatment of non-ulcer dyspepsia. A double-blind placebo-controlled study. Scand J Gastroenterol 1993; 28: 969-72.
46. Kairaluoma MI, Hentilae R, Alavaikko M, et al. Sucralfate versus placebo in treatment of non-ulcer dyspepsia. Am J Med 1987; 83: 51-5.
47. Carvalhinhos A, Fidalgo P, Freire A, Matos L. Cisapride compared with ranitidine in the treatment of functional dyspepsia. Eur J Gastroenterol Hepatol 1995; 7: 411-7.
48. Fumagalli I, Hammer B. Cisapride versus metoclopramide in the treatment of functional dyspepsia. A double-blind comparative trial. Scand J Gastroenterol 1994; 29: 33-7.
49. Halter F, Staub P, Hammer B, Guyot J, Miazza BM. Study with two prokinetics in functional dyspepsia and GORD: domperidone vs. cisapride. J Physiol Pharmacol 1997; 48: 185-92.
50. Van Outryve M, De Nutte N, Van Eeghem P, Gooris JP. Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: a double-blind, placebo-controlled study. Scand J Gastroenterol Suppl 1993; 195: 47-52.
51. Creytens G. Effect of the non-antidopaminergic drug cisapride on postprandial nausea. Curr Ther Res 1984; 36: 1063-70.
52. Testoni PA, Bagnolo F, Fanti L, Passaretti S, Tittobello A. Long-term oral cisapride improves interdigestive antroduodenal motility in dyspeptic patients. Gut 1990; 31: 288-90.
53. Deruyttere M, Lepoutre L, Heylen H, Samain H, Pennoit H. Cisapride in the management of chronic functional dyspepsia: a multicenter, double-blind, placebo-controlled study. Clin Ther 1987; 10: 44-51.
54. Wood SF, Penney SC, Cochran KM. Cisapride in functional dyspepsia: a double-blind, placebo-controlled randomized trial in general practice patients. Scand J Gastroenterol Suppl 1993; 195: 5-10.
55. Holtmann G, Gschossmann J, Mayr P, Talley NJ. A randomised placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. Aliment Pharmacol Ther 2002; 16: 1641-8.
56. Yeoh KG, Kang JY, Tay HH, et al. Effect of cisapride on functional dyspepsia in patients with and without histological gastritis: a double-blind placebo-controlled trial. J Gastroenterol Hepatol 1997; 12: 13-8.
57. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-34.
58. Redstone HA, Barrowman N, Veldhuyzen Van Zanten SJ. H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials. Aliment Pharmacol Ther 2001; 15: 1291-9.
59. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia; a meta-analysis. Am J Gastroenterol 2001; 96: 689-96.
60. Anonymous. From the Food and Drug Administration. J Am Med Assoc 2000; 283: 2228.
61. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. J Am Med Assoc 2000; 284: 3036-9.
62. Nyren O. Secretory abnormalities in functional dyspepsia. Scand J Gastroenterol 1991; 26(Suppl. 182): 25-8.
63. Anonymous. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999; 44(Suppl. 2): S1-16.
64. Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33: 1023-9.